CDK4 and cancer: Even with the present effectiveness of CDK4/6 inhibitors (CDK4/6i), the field of cancer therapy remains in its infancy when it comes to targeting cell-cycle proteins (García-Reyes et al., 2018[40]; Gupta et al., 2023[45]).